Last reviewed · How we verify
CD19 t-haNK
At a glance
| Generic name | CD19 t-haNK |
|---|---|
| Also known as | Rituximab |
| Sponsor | ImmunityBio, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma (PHASE2)
- Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma (PHASE2)
- Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma (PHASE1)
- QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma (PHASE1)
- Study for Subjects with Relapsed/Refractory Non-Hodgkin Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD19 t-haNK CI brief — competitive landscape report
- CD19 t-haNK updates RSS · CI watch RSS
- ImmunityBio, Inc. portfolio CI